Quantcast

Latest valproic acid Stories

2008-12-08 13:12:00

ATLANTA, Dec. 8 /PRNewswire/ -- UCB today announced new findings from analyses of pooled Vimpat(R) (lacosamide) clinical trial data, demonstrating that the new antiepileptic drug (AED) starts working during the first week of treatment and across doses in a challenging patient population, when administered as adjunctive therapy. The analyses also showed that Vimpat(R) provides consistent seizure reduction versus placebo, when added to concomitant AEDs, and that it is generally...

2008-12-05 08:54:35

The cause of autism remains a mystery to the medical community, but researchers have found a link between an epilepsy drug and an increased risk of a child developing autism.A new study shows women who take the epilepsy drug valproate while pregnant may significantly increase their unborn baby's risk of developing autism.In an ongoing study conducted by the Liverpool and Manchester Neurodevelopment Group, researchers are examining 632 children, about half of whom were exposed to epilepsy...

2008-12-03 19:49:06

Prenatal exposure to the epilepsy drug valproate may increase a child's risk of autism, a British researcher says. Lead author Gus Baker of the University of Liverpool said the preliminary results are based on an ongoing study involving 632 children, nearly half of whom were exposed during gestation to epilepsy drugs such as valproate, lamotrigine and carbamazepine. The study, published in the journal Neurology, found mothers who were given valproate during pregnancy were seven times more...

2008-11-12 09:00:45

SOUTH SAN FRANCISCO, Calif., Nov. 12 /PRNewswire/ -- Hyperion Therapeutics, Inc. today reported completion of data analysis for its Phase 2 clinical trial designed to evaluate the safety, tolerability and ammonia scavenging effects of HPN-100 versus BUPHENYL(R) (sodium phenylbutyrate), the current standard of care in patients with urea cycle disorders. Data from the trial will be presented at an upcoming medical conference. (Logo: http://www.newscom.com/cgi-bin/prnh/20070905/AQW076LOGO)...

2008-11-06 09:00:44

Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced financial results for the three-month and nine-month periods ended September 30, 2008. Noven reported net income of $5.2 million, or $0.21 diluted earnings per share, for the quarter ended September 30, 2008. Results for the third quarter of 2008 included the recognition of $5.0 million in operating income due to the reversal of an accrued liability for a Pexeva(R) contingent sales milestone payment and an aggregate $6.0 million...

2008-10-21 09:00:12

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) announced today the presentation of a poster highlighting preclinical synergy of Cyclacel's sapacitabine when given in combination with histone deacetylating agents (HDAC) valproate and vorinostat. The data will be presented at the 20th Annual European Organization for Research and Treatment of Cancer-National Cancer Institute-American Academy of Cancer Research (EORTC-NCI-AACR) Symposium on "Molecular Targets and Cancer...

2008-10-14 09:00:44

SiDMAP, a provider of flux-based, metabolic profiling services, has expanded its SiDTox services to enable rapid and specific detection of drug-induced organ toxicity. Based on research performed by SiDMAP in collaboration with the Center for Metabolomics at the FDA National Center for Toxicological Research, SiDTox now also includes a cost-effective and non-invasive test which promises to better enable pharmaceutical researchers to rapidly detect drug-induced toxicity prior to organ...

b5d2f6635c6ba71ec9c3826b9d336c8d1
2008-10-13 13:15:00

Researchers said on Sunday they found a shortcut to transforming ordinary skin cells into powerful stem cells by "sprinkling" a chemical onto the cells. The team at the Harvard Stem Cell Institute in Massachusetts added the chemical to use just two genes to transform ordinary human skin cells into more powerful induced pluripotent stem cells or iPS cells. "This study demonstrates there's a possibility that instead of using genes and viruses to reprogram cells, one can use chemicals," said Dr....

2008-08-06 09:01:04

Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced financial results for the second quarter and first half of 2008. Noven reported net income of $4.5 million or $0.18 diluted earnings per share for the quarter ended June 30, 2008, including a charge of $1.7 million (discussed below) relating to a previously disclosed voluntary product recall initiated during the quarter. Excluding this charge and related tax effects, Noven would have reported net income of $5.6 million or $0.23 diluted...

2008-07-31 09:01:25

By John Dorschner, The Miami Herald Jul. 31--Noven Pharmaceuticals, the drug maker with headquarters in South Miami-Dade, said the U.S. Food and Drug Administration has approved Stavzor, a delayed-release capsule used to treat patients with bipolar disorder, certain types of seizures and migraine headaches. Stavzor will be the first pipeline drug to reach the marketplace that was developed by Noven Therapeutics, a subsidiary specializing in medications that don't use patches, said Noven...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related